Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Molecular marker with auxiliary functions of early diagnosis and prognosis monitoring on colorectal cancer, and application thereof

A technology of colorectal cancer and metabolic markers, applied in the field of biological detection, can solve the problems of high missed diagnosis rate, high detection cost, difficulty in large-scale population screening, etc., and achieve the effect of improving accuracy

Inactive Publication Date: 2017-08-18
SHENZHEN UNIV
View PDF3 Cites 26 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Fecal occult blood test is the most common screening method, but it is prone to false positives and has a high rate of missed diagnosis
The detection of fecal shedding markers is a new technology, which is expensive and difficult to use for large-scale p

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Molecular marker with auxiliary functions of early diagnosis and prognosis monitoring on colorectal cancer, and application thereof
  • Molecular marker with auxiliary functions of early diagnosis and prognosis monitoring on colorectal cancer, and application thereof
  • Molecular marker with auxiliary functions of early diagnosis and prognosis monitoring on colorectal cancer, and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1 Screening of differential metabolic markers based on GC-TOF-MS and UPLC-Q-TOF-MS platforms

[0047] 1. Sampling

[0048] Clinical sample 1: Serum from 101 colorectal cancer patients (CRC patients) and 102 healthy controls were collected, numbered and stored in a -80°C refrigerator. The samples of colorectal cancer patients came from the inpatients of Ruijin Hospital Affiliated to Shanghai Jiaotong University, and the samples of the healthy control group came from the physical examination center of Ruijin Hospital Affiliated to Shanghai Jiaotong University. 62 colorectal cancer patients and 62 healthy controls were randomly selected as the training sample set, and the remaining 39 colorectal cancer patients and 40 healthy controls were selected as the test sample set. The relevant clinical information is shown in Table 1. All clinical samples of the present invention have been approved by the Ethics Committee of Ruijin Hospital Affiliated to Shanghai Jiao Tong...

Embodiment 2

[0102] Example 2 ROC Analysis of Metabolic Diagnostic Markers Clinically Distinguishing CRC Patients and Healthy People

[0103] 1. Sampling

[0104] Sample collection is the same as clinical sample 1 in Example 1.

[0105] 2. Serum sample pretreatment and detection

[0106] Serum processing and detection methods are the same as in Example 1.

[0107] 3. Data processing

[0108] Data processing method is also the same as embodiment 1

[0109] 4. ROC analysis

[0110] 1. ROC analysis of β-hydroxybutyric acid

[0111] The statistical analysis software SPSS (v19, IBM, USA) was used for ROC analysis. The result is as image 3 Shown: In the training sample set and the test sample set, the area under the curve (AUC value) of using serum β-hydroxybutyric acid level to distinguish CRC patients and healthy people is as high as 0.925 and 0.951, respectively, and its diagnostic sensitivity is higher than that of 90%, and the specificity is over 80%.

[0112] 2. ROC analysis of 1...

Embodiment 3

[0115] Example 3 Analysis of metabolic markers in colorectal cancer patients with different pathological stages

[0116] 1. Sampling

[0117] Sample collection is the same as clinical sample 1 in Example 1.

[0118] 2. Serum sample pretreatment and detection

[0119] Serum processing and detection methods are the same as in Example 1.

[0120] 3. Data processing

[0121] Data processing method is also the same as embodiment 1.

[0122] 4. According to the analysis of clinicopathological data, fumaric acid decreases successively with the increase of pathological severity (stage I → stage IV) (such as Figure 5 shown), and there was a significant difference (p=0.03) between early patients (stage I + stage II) and advanced patients (stage III + stage IV). Serum β-hydroxybutyric acid has been significantly increased in early CRC patients, and it increases sequentially with the increase of pathological severity (stage I → stage IV) (such as Figure 6 shown).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a metabolism marker for screening and monitoring a colorectal cancer. The metabolism marker is beta-hydroxybutyrate, 5-hydroxytryptamine, lysophosphatidyl choline (C14:0), lysophosphatidyl choline (C16:1), alpha-ketobutyrate, fumaric acid, aspartic acid, 2-octene diacid, glycerin, glyceric acid, tryptophan, aconitate, citric acid, ornithine, glycerol monopalmitate, creatinine, methionine and citrulline. The invention also provides a kit with auxiliary functions of early diagnosis and prognosis monitoring on the colorectal cancer. The application of the micromolecule metabolism marker to monitoring of the colorectal cancer not only greatly improves the accuracy, but also has great guiding significance for development of a subsequent clinical application study.

Description

technical field [0001] The invention relates to the field of biological detection, in particular to molecular markers related to early screening and prognosis monitoring of colorectal cancer and applications thereof. Background technique [0002] Colorectal cancer (CRC) is one of the four most common malignant tumors in humans today. There are more than one million new cases of colorectal cancer every year in the world, and its mortality rate is as high as 33%, ranking among all cancers. the third. In my country, the morbidity and mortality of colorectal cancer are increasing year by year, and showing a younger trend. The occurrence and development of colorectal cancer is a multi-factor and multi-step process, and the pathogenesis is not yet fully understood. At present, the 5-year survival rate of CRC patients is still lower than 60%, and the clinical efficacy evaluation and prognosis monitoring need to be further improved. The survival rate of CRC patients is closely re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/574G01N30/02G01N30/72G01N30/86
CPCG01N33/57419G01N30/02G01N30/72G01N30/86G01N30/8631G01N33/574G01N33/57446G01N33/57473G01N33/57484G01N2570/00G01N2800/065
Inventor 谭斌斌付利张延向迪
Owner SHENZHEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com